Patterns Of Care

Dr Lisa A Carey from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, and Dr Rita Nanda from The University of Chicago in Illinois engage in an evidence-based discussion around real-world cases involving common toxicities associated with antibody-drug conjugates in the management of breast cancer.CME information and select publications here.

Dr Yelena Janjigian from Memorial Sloan Kettering Cancer Center in New York, New York, discusses updates across the treatment landscape for gastroesophageal cancers, as well as real-world clinical case examples.CME information and select publications here.

Dr Terence Friedlander from the UCSF Helen Diller Family Comprehensive Cancer Center and Dr Rana R McKay from the UC San Diego Moores Cancer Center summarize the treatment landscape for prostate and urothelial bladder cancer and discuss the implications of clinical findings recently presented at the ESMO Congress 2025.CME information and select publications here.

Dr Luis Paz-Ares from the Spanish National Oncology Research Center in Madrid and Dr Shields from Indiana University School of Medicine in Indianapolis discuss key datasets surrounding first-line and maintenance therapy for patients with extensive-stage small cell lung cancer and their clinical implications. CME information and select publications here.

Dr Manish A Shah from Weill Cornell Medicine in New York, New York, summarizes the treatment landscape and reviews relevant clinical datasets for patients with gastroesophageal cancers.     CME information and select publications here.

Dr Gottfried E Konecny from the University of California, Los Angeles, summarizes the treatment landscape and reviews relevant clinical datasets for patients with ovarian cancer. CME information and select publications here.

Dr Kerry A Rogers from The Ohio State University in Columbus summarizes the treatment landscape and reviews relevant clinical datasets for patients with chronic lymphocytic leukemia. CME information and select publications here.

Dr Justin F Gainor, Dr Corey J Langer and Dr Misty Dawn Shields summarize the treatment landscape and review relevant clinical datasets for patients with lung cancer.CME information and select publications here.

Dr Jeremy S Abramson from Massachusetts General Hospital in Boston and Dr Loretta J Nastoupil from CommonSpirit Mercy Hospital in Durango, Colorado, discuss the clinical applications of chimeric antigen receptor T-cell therapy for patients with non-Hodgkin lymphoma.   CME information and select publications here.

Dr John Heymach from The University of Texas MD Anderson Cancer Center in Houston discusses recent updates on available and novel treatment strategies for HER2-altered non-small cell lung cancer.   CME information and select publications here.

Prof Giuseppe Curigliano from the European Institute of Oncology in Milan, Italy, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood, Kansas, discuss the implications of clinical findings in breast cancer recently presented at the 2025 ESMO Annual Meeting. CME information and select publications here.

Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer and discusses the implications of recently presented clinical findings from the ESMO Congress 2025. CME information and select publications here.

Dr Matthew Lunning from the Fred and Pamela Buffett Cancer Center in Omaha, Nebraska, discusses recent updates on the management of toxicities associated with CAR T-cell therapy.   CME information and select publications here.

Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer and discusses the implications of recently presented clinical findings from the ESMO Congress 2025. CME information and select publications here.

Dr Rinath M Jeselsohn and Dr Joyce O’Shaughnessy review current literature and datasets exploring the use of oral selective estrogen receptor degraders for the management of metastatic breast cancer. CME information and select publications here.

Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer and discusses the implications of recently presented clinical findings from the ESMO Congress 2025. CME information and select publications here.

Dr Tanios Bekaii-Saab and Dr Kristen K Ciombor summarize the treatment landscape and review key datasets in consideration of HER2-directed therapies for patients with HER2-positive gastrointestinal cancers. CME information and select publications here.

Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, reviews available clinical data with PROTAC estrogen receptor degraders and their potential role in the management of HR-positive metastatic breast cancer. CME information and select publications here.

Dr Jeremy S Abramson from Massachusetts General Hospital in Boston and Dr Manali Kamdar from the University of Colorado Cancer Center in Aurora discuss patient questions and experiences with CAR T-cell therapy for non-Hodgkin lymphoma. Educational information and select publications here.

Prof Francois-Clement Bidard from the Institut Curie in Paris, France, Dr Hope S Rugo from the City of Hope Comprehensive Cancer Center in Duarte, California, Dr Rebecca Shatsky from the University of California San Diego Moores Cancer Center and Dr Seth Wander from Massachusetts General Hospital in Boston discuss recent updates on available and emerging treatment strategies involving oral SERDs for ER-positive metastatic breast cancer.  CME information and select publications here.